Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/66—Phosphorus compounds
  • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
  • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/04—Immunostimulants

Definitions

• the present invention generally relates to stimulating an immune response, and more particularly to the use of the R and S enantiomers of lipids in stimulating immune responses.
• immunologic modifiers that enhance, direct, or promote an immune response
• vaccines may include antigens to stimulate an immune response.
• some potential vaccines that include antigens are weak stimulators of an immune response because the vaccines do not efficiently deliver the antigen to antigen presenting cells (“APC”) of the immune system and/or the antigen is weakly immunogenic.
• an immunomodifier when included as part of a therapeutic vaccine, should at least (1) improve antigen delivery and/or processing in the APC [Wang, R, F., and Wang, H. Y. Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cells.
• the primary class of agents used to enhance the efficacy of antigens, such as peptide or protein antigens, in eliciting an immune response are adjuvants such as water-in- oil emulsions, alum, and other chemicals which enhance antigen responses; however, these adjuvants are not immunomodifiers, as described above, because they have no direct immunomodulatory effects themselves [Vogel, F. R., and Powell, M. F. A compendium of vaccine adjuvants and excipients, Pharm Biotechnol 6: 141 (1995)].
• adjuvants such as water-in- oil emulsions, alum, and other chemicals which enhance antigen responses; however, these adjuvants are not immunomodifiers, as described above, because they have no direct immunomodulatory effects themselves [Vogel, F. R., and Powell, M. F. A compendium of vaccine adjuvants and excipients, Pharm Biotechnol 6: 141 (1995)].
• influenza virosomes In addition to traditional adjuvants such as the aluminum salts, products such as influenza virosomes [Gtuck, R., and Walti, E. 2000. Biophysical validation ofEpaxal Berna, a hepatitis A vaccine adjuvanted with immunopotentia ⁇ ng reconstituted influenza virosomes (IRIV). Dev Biol (Basel) 103 :189 (2000)], and Chiron's MF59 [Kahn, J. O., et al.
• some antigens are weak stimulators of an immune response.
• a weakly immunogenic antigen in addition to co-administering antigen with substances that stimulate immune responses, as described above, can be modified to increase its immunogenicity.
• a weakly immunogenic antigen can be coupled to immunogenic peptides, polysaccharides, or lipids to increase its imnranogenicity.
• simply coupling weakly immunogenic antigens to these types of compounds may not be sufficient to elicit an immune response.
• the resulting immune response may be directed to immunogenic epitopes on the coupled compound and not the weak antigen, or the coupled antigen may not be efficiently delivered to APC of the immune system.
• additional methods are needed to stimulate immune responses to antigens that are weakly immunogenic.
• This invention is directed to the chirality of cationic lipids and the use of the R and S enantiomers of cationic lipids, which under certain dose and composition conditions act as a novel class of immune-stimulants, to (1) effectively present or deliver an antigen to the immune system and (2) stimulate the immune system to respond to the antigen.
• Liposomes have been extensively used for delivering small molecular weight drugs, plasmid DMA, oligonucleotides, proteins, and peptides. Vaccines using liposomal vehicles as nonviral antigen carriers are preferable compared to traditional immunizations using live attenuated vaccines or viral vectors such as vaccinia or influenza virus.
• R enantiomer under various dose conditions (including low dose conditions), induces strong immune responses specific to the antigen formulated in the complex and results in tumor regression.
• Complexes consisting of S-DOTAP and the antigen however were able to induce only limited tumor regression, and not at all doses at which R-DOTAP was effective.
• Both enantiomers of DOTAP are however equally effective at inducing maturation and activation of dendritic cells, which is the first step in inducing a cellular immune response.
• one aspect of the invention provides a composition of at least one enantiomer of a cationic lipid in a dose sufficient to induce an immune response in a subject.
• Another aspect of the invention provides a method of inducing an immune response in a subject by administering a specific enantiomer or a mixture of enantiomers of a cationic lipid to the subject.
• Another aspect of the invention provides a composition of an R or S enantiomer of a cationic lipid in a dose sufficient to induce an immune response in a subject.
• Figs. IA and IB depict chirality of l,2-dio ⁇ eoyl-3-t ⁇ methylammoninum propane
• Fig. 2 is a graph depicting activation of human dendritic cells resulting in expression of the co-stimulatory molecule CD SO by R-DOTAP, S-DOTAP and the racemic mixture RS-
• Fig. 3 is a graph depicting activation of human dendritic cells resulting in expression of the co-stimulatory molecule CD 83 by R-DOTAP, S-DOTAP and the racemic mixture RS-
• Fig. 4 is a graph depicting activation of human dendritic cells resulting in expression of the co-stimulatory molecule CD 86 by R-DOTAP, S-DOTAP and the racemic mixture RS-
• Fig. 5 is a graph depicting stimulation of human dendritic cells resulting in production of the chemokine CCL- 3 by R-DOTAP, S-DOTAP and the racemic mixture RS-DOTAP
• Fig. 6 is a graph depicting stimulation of human dendritic cells resulting in production of the chemokine CCL-4 by R-DOTAP, S-DOTAP and the racemic mixture RS-DOTAP .
• Fig. 7 is a graph depicting stimulation of human dendritic cells resulting in production of the chemokine CCL-5 by R-DOTAP, S-DOTAP and the racemic mixture RS-DOTAP
• Fig. 8 is a graph depicting stimulation of human dendritic cells resulting in production of the chemokine CCL-19 by R-DOTAP, S-DOTAP and the racemic mixture RS-DOTAP.
• Fig. 9 is a graph depicting stimulation of human dendritic cells resulting in production of the cytokine IL-2 by R-DOTAP, S-DOTAP and the racemic mixture RS-DOTAP.
• 0025J Fig. 10 is a graph depicting stimulation of human dendritic cells resulting in production of the cytokine IL-8 by R-DOTAP, S-DOTAP and the racemic mixture RS-
• Fig. Il is a graph depicting stimulation of human dendritic cells resulting in production of the cytokine IL-12 by R-DOTAP, S-DOTAP and the racemic mixture RS-
• Fig. 12 is a graph demonstrating the in vivo antitumor effect of various doses of a cationic lipid/antigen complex based on tumor size and time post-injection.
• Fig. 13 is a graph demonstrating the effect of S-DOTAP dose on the in vivo anti tumor efficacy of the cationic lipid/antigen complex.
• Fig. 14 is a graph demonstrating the effect of R-DOTAP dose on the in vivo anti tumor efficacy of (he cationic lipid/antigen complex,
• Fig- ⁇ 5 is a graph depicting the lipid dose response effects of the racemic mixture of
• DOTAP DOTAP
• R-DOTAP S-DOTAP
• S-DOTAP S-DOTAP
• * p ⁇ 0.05, ** p ⁇ 0.01, n 5-6.
• One aspect of the present invention provides an enantiomer of a cationic lipid to stimulate an immune response in a mammal to prevent or treat disease.
• the individual chiral lipids can function independently as immunomodulators, in a dose dependent manner, such as for production of chemokines and/or cytokines, by activating various components of the MAP kinase signaling pathway.
• the dose range that effectively induces an immune response is observed to differ between the R and S enantiomers and also within various mammalian species.
• the R-enantiomer of DOTAP effectively attenuates tumor growth over a range of about 30 nmole to about 400 nmole.
• the S-enantiomer of DOTAP is effective over this same range of doses in the same species of rodent, though less so than the R-enantiomer.
• the chiral cationic lipid may be associated with antigens or drugs for presentation to cells of the immune system while simultaneously stimulating a strong antigen-specific immune response.
• the antigen is a lipopeptide.
• US. Patent No. 7,303,881 discloses that multiple cationic lipids complexed with disease-associated antigens were shown to stimulate a prophylactic immune response that prevented the specific disease (e.g., HPV- positive cancer) and also a therapeutic immune response that killed cells expressing the particular antigen and resulted in an effective treatment of the disease.
• a prophylactic immune response that prevented the specific disease (e.g., HPV- positive cancer)
• a therapeutic immune response that killed cells expressing the particular antigen and resulted in an effective treatment of the disease.
• studies were performed to further understand the effects of chirality on the immuno stimulatory capability of cationic lipids by using the R and S ena ⁇ tiomers of DOTAP. (The R and S enantiomers of DOTAP are shown in Figs. IA and IB).
• the chira] cationic lipid at a dose sufficient to stimulate an immune response, is administered in combination with an antigen or antigens.
• the cationic lipid/antigen combination is capable of generating an immune response that is specific to the antigen(s) delivered in combination with the cationic lipid.
• the response generated may include production of specific cytotoxic T cells, memory T cells, or B cells resulting in the prevention of, or therapeutic response to, the specific disease associated with the antigen(s).
• the chiral cationic lipids of the invention maybe in the form of cationic lipid complexes.
• the cationic lipid complex can take the form of various vesicles such as liposomes, micelles, or emulsions.
• the cationic lipid complexes maybe unilaminar or multilaminar.
• the antigen maybe encapsulated in the cationic lipid complex or may be unencapsulated. Encapsulated is understood to mean that the antigen may be contained within the internal space of the complex and/or incorporated into the lipid walls of the complex.
• Another aspect of the invention relates to a method for producing these complexes, wherein the method may optionally include the step of purifying these formulations from excess individual components.
• the cationic lipid complexes have a net positive charge and/or a positively charged surface at pH 6.0-8,0.
• the optional "antigen" which may be included with cationic lipid complexes of the invention may be nucleic acids, peptides, lipopeptides, proteins, lipoproteins, polysaccharides, and other macromolecules which may be complexed directly with cationic lipids.
• cationic drugs e.g., large cationic protein
• anionic lipid or sequentially complexed first with anionic lipid or polymer followed by the chiral cationic lipid permits delivery of positive or neutral charged drugs to cells by the complexes of the present invention.
• One aspect of the present invention involves the use of the chiral cationic lipid complexes to activate dendritic cells and also to stimulate the production of chemokines and cytokines.
• Chemokines and cytokines are important regulators of immune responses. Chemokines were originally identified as potent chemoattractants for inflammatory cells including neutrophils, eosinophils, and monocytes/macrophages. Subsequent studies have revealed that chemokines have profound effects on immune reactions by regulating the trafficking of dendritic cells and other lymphocytes into lymphoid organs. Dendritic cells are migratory cells that sample antigens in the tissue, migrate to the draining lymph nodes and mature to stimulate the T cell response.
• CCL2 cytotoxic T lymphocytes
• CCL-4 Another CC chemokine, CCL-4, has also been shown to recruit and expand dendritic cells in vivo and potentiate the immunogenicity of plasmid DNA vaccines. Recently, it has been shown that chernokines enhance immunity by guiding na ⁇ ve CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction and promote memory CD8+ T cell generation.
• cbemokines that may be stimulated by the cationic lipid complexes of the present invention are CCL-2, CCL-3, and CCL-4.
• the chiral cationic lipid complexes of the present invention may form liposomes that are optionally mixed with antigen and may contain the chiral cationic lipids alone or chiral cationic lipids in combination with neutral lipids.
• Suitable chiral cationic lipid species include, but are not limited to the R and S enantiomers of: 3-P[ 4 N-( 1 N, 8 -diguanidino sperm idine)-carbamoyl] cholesterol (BGSC); 3- ⁇ [N,N-diguanidinoethyl-aminoethane)- carbamoyl] cholesterol (BGTC); N> Ti N 2 N 3 Tetra-methyttetrapahnitylspermine (cellfectin); N-t-butyl-N'-tetradecyl-S-tetradecyl-aminopropion-amidine (CLONfectin); dimethyldioctadecyl ammonium bromide (DDAB); l ,2-dimyristyloxypiOpyl-3-dimethyl- hydroxy ethyl ammonium bromide (DMRIE); 2,3-dioleoyloxy-N-
• nonsteroidal chiral cationic lipids having a structure represented by the following formula:
• R 1 is a quaternary ammonium group
• Y 1 is chosen from a hydrocarbon chain, an ester, a ketone, and a peptide
• C* is a chiral carbon
• R 2 and R 3 are independently chosen from a saturated fatty acid, an unsaturated fatty acid, an ester-linked hydrocarbon, phosphor- diesters, and combinations thereof.
• DOTAP, DMTAP, DSTAP, DPTAP, DPEPC, DSEPC, DMEPC, DLEPC, DOEPC, DMKE, DMKD, DOSPA, DOTMA are examples of lipids having this general structure.
• chiral cationic lipids of the invention are lipids in which bonds between the lipophilic group and the amino group are stable in aqueous solution.
• bonds used in the cationic lipids include amide bonds, ester bonds, ether bonds and carbamoyl bonds.
• liposomes comprising two cationic lipid species, lysyl- phosphatidylelhanolainme and ⁇ -alanyl cholesterol ester have been disclosed for certain drug delivery applications [Brunette, E. et al., Nucl. Acids Res., 20: 1151 (1992)].
• the methods of the invention are not restricted only to the use of the cationic lipids recited above but rather, any lipid composition may be used so long as a cationic liposome is produced and the resulting cationic charge density is sufficient to activate and induce an immune response.
• the complexes of the invention may contain other lipids in addition to the chiral cationic lipids.
• lipids include, but are not limited to, lyso lipids of which lysophosphatidylcholine (1-oleoyl lysophosphatidylcholine) is an example, cholesterol, or neutral phospholipids including dioleoyl phosphatidyl ethanolamine (DOPE) or dioleoyl phosphatidylcholine (DOPC) as well as various lipophilic surfactants, containing polyethylene glycol moieties, of which Tween-80 and PEG-PE are examples.
• DOPE dioleoyl phosphatidyl ethanolamine
• DOPC dioleoyl phosphatidylcholine
• various lipophilic surfactants containing polyethylene glycol moieties, of which Tween-80 and PEG-PE are examples.
• the chiral cationic lipid complexes of the invention may also contain negatively charged lipids as well as cationic lipids so long as the net charge of the complexes formed is positive and/or the surface of the complex is positively charged.
• Negatively charged lipids of the invention are those comprising at least one lipid species having a net negative charge at or near physiological pH or combinations of these. Suitable negatively charged lipid species include, but are not limited to, CHEMS (cholesteryl hemisuccinate), NGPE (N-glutaryl phosphatidlylethanolanine), phosphatidyl glycerol and phosphatidic acid or a similar phospholipid analog.
• the chiral cationic lipid is present in the liposome at from about 10 mole % to about 100 mole % of total liposomal lipid, or from about 20 mole % to about 80 mole %.
• the neutral lipid when included in the liposome, may be present at a concentration of from about 0 mole % to about 90 mole % of the total liposomal lipid, or from about 20 mole % to about 80 mole %, or from 40 mole % to 80 mole %.
• the negatively charged lipid when included in the liposome, maybe present at a concentration ranging from about 0 mole % to about 49 mole % of the total liposomal lipid, or from about 0 mole % to about 40 mole %.
• the liposomes contain a chiral cationic and a neutral lipid, in ratios between about 2:8 to about 6:4.
• the complexes of the present invention may contain modified lipids, protein, polycations or receptor ligands which function as a targeting factor directing the complex to a particular tissue or cell type.
• targeting factors include, but are not limited to, asialoglycoprotein, insulin, low density lipoprotein (LDL), folate and monoclonal and polyclonal antibodies directed against cell surface molecules.
• LDL low density lipoprotein
• the positive surface charge can be sterically shielded by incorporating lipophilic surfactants which contain polyethylene glycol moieties.
• the cationic lipid complexes may be stored in isotonic sucrose or dextrose solution upon collection from the sucrose gradient or they may be lyophilized and then reconstituted in an isotonic solution prior to use.
• the cationic lipid complexes are stored in solution.
• the stability of the cationic lipid complexes of the present invention is measured by specific assays to determine the physical stability and biological activity of the cationic lipid complexes over time in storage.
• the physical stability of the cationic lipid complexes is measured by determining the diameter and charge of the cationic lipid complexes by methods known to those of ordinary skill in the art, including for example, electron microscopy, gel filtration chromatography or by means of quasi -elastic light scattering using, for example, a Coulter N4SD particle size analyzer as described in the Example.
• the physical stability of the cationic lipid complex is "substantially unchanged" over storage when the diameter of the stored cationic lipid complexes is not increased by more than 100%, or by not more than 50%, or by not more than 30%, over the diameter of the cationic lipid complexes as determined at the time the cationic lipid complexes were purified.
• compositions using the chiral cationic lipid complexes of the invention may comprise the cationic lipid complexes in a physiologically compatible sterile buffer such as, for example, phosphate buffered saline, isotonic saline or low ionic strength buffer such as acetate or Hepes (an exemplary pH being in the range of about 3.0 to about 8.0).
• a physiologically compatible sterile buffer such as, for example, phosphate buffered saline, isotonic saline or low ionic strength buffer such as acetate or Hepes (an exemplary pH being in the range of about 3.0 to about 8.0).
• the chiral cationic lipid complexes may be administered as aerosols or as liquid solutions for intratumoral, intraarterial, intravenous, intratracheal, intraperitoneal, subcutaneous, and intramuscular administration.
• the formulations of the present invention may incorporate any stabilizer known in the art.
• Illustrative stabilizers are cholesterol and other sterols that may help rigidify the liposome bilayer and prevent disintegration or destabilization of the bilayer.
• agents such as polyethylene glycol, poly-, and monosaccharides maybe incorporated into the liposome to modify the liposome surface and prevent it from being destabilized due to interaction with blood- components.
• Other illustrative stabilizers are proteins, saccharides, inorganic acids, or organic acids which may be used either on their own or as admixtures.
• a number of pharmaceutical methods may be employed to control, modify, or prolong the duration of immune stimulation.
• Controlled release preparations may be achieved through the use of polymer complexes such as polyesters, polyamino acids, methylcellulose, polyvinyl, poly(lactic acid), and hydro gels to encapsulate or entrap the cationjc lipids and slowly release them. Similar polymers may also be used to adsorb the liposomes.
• the liposomes may be contained in emulsion formulations in order to alter the release profile of the stimulant.
• the duration of the stimulant's presence in the blood circulation maybe enhanced by coating the surface of the liposome with compounds such as polyethylene glycol or other polymers and other substances such as saccharides which are capable of enhancing the circulation time or half life of liposomes and emulsions.
• the chiral cationic lipids may be combined with typical pharmaceutical carriers known in the art such as, for example, sucrose, lactose, methylcellulose, carboxymethyl cellulose, or gum Arabic, among others, The cationic lipids may also be encapsulated in capsules or tablets for systemic delivery.
• Administration of the chiral cationic lipid of the present invention may be for either a prophylactic or therapeutic purpose. When provided prophylactically, the cationic lipid is provided in advance of any evidence or symptoms of illness. When provided therapeutically, the cationic lipid is provided at or after the onset of disease. The therapeutic administration of the immune-stimulant serves to attenuate or cure the disease.
• the cationic lipid may be administered with an additional therapeutic agent(s) or antigen(s).
• the cationic lipids are administered with an additional therapeutic agent or antigen, the prophylactic or therapeutic effect may be generated against a specific disease.
• the formulations of the present invention both for veterinary and for human use, comprise a chiral cationic lipid alone as described above, as a mixture of R and S enantiomers, or also optionally, with one or more therapeutic ingredients such as an antigen(s) or drug molecule(s).
• the formulations may conveniently be presented in unit dosage form and may be prepared by any method known in the pharmaceutical ait [0058] ANTIGENS
• the chiral cationic lipid is administered without any additional agents in order to boost or lower various immune responses, including production of other immune modulators, and to boost the immune response to fighting disease.
• the chiral cationic lipid is administered in combination with an antigen or antigens.
• the objective is to generate an immune response, which is specific to the antigen(s) delivered in combination with the cationic lipid.
• the response generated may include production of specific cytotoxic T-cells, memory T-cells, or B-cells resulting in the prevention of or therapeutic response to the specific disease associated with those antigen(s).
• the antigen can be any tumor-associated antigen or microbial antigen or any other antigen known to one skilled in the art.
• a "tumor-associated antigen,” as used herein is a molecule or compound (e.g., a protein, peptide, polypeptide, lipoprotein, lipopeptide, glycoprotein, glycopeptides, lipid, glycolipid, carbohydrate, RNA, and/or DNA) associated with a tumor or cancer cell and which is capable of provoking art immune response (humoral and/or cellular) when expressed on the surface of an antigen presenting cell in the context of a major histocompatibility complex ("MHC”) molecule.
• MHC major histocompatibility complex
• Tumor- associated antigens include self antigens, as well as other antigens that may not be specifically associated with a cancer, but nonetheless enhance an immune response to and/or reduce the growth of a tumor or cancer cell when administered to an animal. More specific embodiments are provided herein.
• a "microbial antigen,” as used herein, is an antigen of a microorganism and includes, but is not limited to, infectious virus, infectious bacteria, infectious parasites and infectious fungi.
• Microbial antigens may be intact microorganisms, and natural isolates, fragments, or derivatives thereof, synthetic compounds which are identical to or similar to naturally- occurring microbial antigens and, preferably, induce an immune response specific for the corresponding microorganism (from which the naturally- occurring microbial antigen originated).
• a compound is similar to a naturally-occurring microorganism antigen if it induces an immune response (humoral and/or cellular) similar to a naturally-occurring microorganism antigen.
• a naturally-occurring microorganism antigen is well known to those of ordinary skill in the art such as, for example, a protein, peptide, polypeptide, lipoprotein, lipopeptide, glycoprotein, glycopeptides, lipid, glycolipid, carbohydrate, RNA, and/or DNA.
• a compound that is similar to a naturally-occurring microorganism antigen is a peptide mimic of a polysaccharide antigen. More specific embodiments are provided herein.
• the term "antigen" is further intended to encompass peptide or protein analogs of known or wild-type antigens such as those described in this specification.
• the analogs may be more soluble or more stable than wild type antigen, and may also contain, mutations or modifications rendering the antigen more immunologically active.
• Antigen can be modified in any manner, such as adding lipid or sugar moieties, mutating peptide or protein amino acid sequences, mutating the DNA or RNA sequence, or any other modification known to one skilled in the art.
• Antigens can be modified using standard methods known by one skilled in the art.
• compositions and methods of the present invention are peptides or proteins which have amino acid sequences homologous with a desired antigen's amino acid sequence, where the homologous antigen induces an immune response to the respective tumor, microorganism or infected cell.
• the antigen in the cationic lipid complex comprises an antigen associated with a tumor or cancer, i.e., a tumor-associated antigen, to make a vaccine to prevent or treat a tumor.
• the tumor or cancer vaccines of the present invention further comprise at least one epitope of at least one tumor-associated antigen.
• the tumor or cancer vaccines of the present invention further comprise a plurality of epitopes from one or more tumor-associated antigens.
• the tumor-associated antigens finding use in the cationic lipid complexes and methods of the present invention can be inherently immunogenic, or nonimm ⁇ nogenic, or slightly immunogenic.
• antigens include, but are not limited to, synthetic, recombinant, foreign, or homologous antigens
• antigenic materials may include but are not limited to proteins, peptides, polypeptides, lipoproteins, lipopeptides, lipids, glycolipids, carbohydrates, RNA and DNA.
• Such vaccines include, but are not limited to, those for the treatment or prevention of breast cancer, head and neck cancer, melanoma, cervical cancel', lung cancer, prostate cancer, gut carcinoma, or any other cancer known in the art using a cationic lipid in a complex with a tumor-associated antigen(s). It is also possible to formulate the antigen with the cationic lipid without encapsulating it in the liposome.
• the cliiral cationic lipid complexes of the present invention may be used in methods to treat or prevent cancer.
• the mammal to be immunized maybe injected with the pharmaceutical formulation containing the liposome with the encapsulated antigen(s).
• Tumor-associated antigens suitable for use in the present invention include both naturally occurring and modified molecules which may be indicative of single tumor type, shared among several types of tumors, and/or exclusively expressed or overexpressed in tumor cells in comparison with normal cells.
• proteins, glycoproteins, lipoproteins, peptides, and lipopeptides tumor-specific patterns of expression of carbohydrates, gangliosides, glycolipids, and mucins have also been documented.
• Exemplary tumor-associated antigens for use in cancer vaccines include protein products of oncogenes, tumor suppressor genes, and other genes with mutations or rearrangements unique to tumor cells, reactivated embryonic gene products, oncofetal antigens, tissue-specific (but not tumor-specific) differentiation antigens, growth factor receptors, cell surface carbohydrate residues, foreign viral proteins, and a number of other self proteins.
• tumor- associated antigens include, e.g., mutated or modified antigens such as the protein products of the Ras p21 protooncogenes, tumor suppressor p53 and HER-2/neu and BCR-abl oncogenes, as well as CDK4, MUMl , Caspase 8, and Beta catenin; overexpressed antigens such as galectin 4, galectin 9, carbonic anhydrase, Aldolase A, PRAME, He ⁇ 2/neu, ErbB-2 and KSA, oncofetal antigens such as alpha fetoprotein (AFP), human chorionic gonadotropin (hCG); self antigens such as carcinoembryonic antigen (CEA) and melanocyte differentiation antigens such as Mart 1/Melan A, gplOO, gp75, Tyrosinase, TRPl and TRP2; prostate associated antigens such as PSA, PAP, PSMA, PSM-Pl
• tumor-associated antigens are wJiole cell and tumor cell lysates as well as immunogenic portions thereof, as well as immunoglobulin idiotypes expressed on monoclonal proliferations of B lymphocytes for use against B cell lymphomas.
• Tumor-associated antigens and their respective tumor cell targets include, e.g., cytokeratins, particularly cytokeratin 8, 18 and 19, as antigens for carcinoma.
• Epithelial membrane antigen (EMA), human embryonic antigen (HEA-125), human milk fat globules, MBrI 3 MBr8, Ber-EP4, 17-1 A, C26 and Tl ⁇ are also known carcinoma antigens.
• Desmin and muscle-specific actin are antigens of myogenic sarcomas.
• Placental alkaline phosphatase, beta-human chorionic gonadotropin, and alpha- fetoprotein are antigens of trophoblastic and germ cell tumors.
• Prostate specific antigen is an antigen of prostatic carcinomas, card no embryonic antigen of colon adenocarcinomas.
• HMB-45 is an antigen of melanomas.
• useful antigens could be encoded by human papilloma virus.
• Chromagranin-A and synaptophysin are antigens of neuroendocrine and neuroectodermal tumors. Of particular interest are aggressive tumors that form solid tumor masses having necrotic areas. The lysis of such necrotic cells is a rich source of antigens for antigen- presenting cells, and thus the subject therapy may find advantageous use in conjunction with conventional chemotherapy and/or radiation therapy.
• the human papillomavirus HPV antigens are used.
• a specific HPV antigen that used as a tumor-associated antigen is HPV subtype 16 E7.
• HPV E7 antigen- cationic lipid complexes are effective at preventing and treating cervical cancer.
• a genetically engineered E7 protein, i.e., E7m protein, having antigenic activity, but without tumorigenic activity is an effective tumor-associated antigen.
• E7m-cationic lipid complexes induce cellular immunity to cause complete regression of established tumors and, thus, are useful as potent anti-cervical cancer vaccines,
• Tumor-associated antigens can be prepared by methods well known in the art.
• these antigens can be prepared from cancer cells either by preparing crude extracts of cancer cells (e.g., as described in Cohen et al, Cancer Res., 54:1055 (1994)), by partially purifying the antigens, by recombinant technology, or by de novo synthesis of known antigens.
• the antigen may also be in the form of a nucleic acid encoding an antigenic peptide in a form suitable for expression in a subject and presentation to the immune system of the immunized subject.
• the antigen may be a complete antigen, or it may be a fragment of a complete antigen comprising at least one epitope.
• Antigens derived from pathogens known to predispose to certain cancers may also be advantageously included in the cancer vaccines of the present invention. It is estimated that close to 16% of the worldwide incidence of cancer can be attributed to infectious pathogens; and a number of common malignancies are characterized by the expression of specific viral gene products. Thus, the inclusion of one or more antigens from pathogens implicated in causing cancer may help broaden the host immune response and enhance the prophylactic or therapeutic effect of the cancer vaccine.
• Pathogens of particular interest for use in the cancer vaccines provided herein include the, hepatitis B virus (hepatocellular carcinoma), hepatitis C vims (heptomas), Epstein Ban- vims (EBV) (Burkitt lymphoma, nasopharynx cancer, PTLD in immuno suppressed individuals), HTLVL (adult T cell leukemia), oncogenic human papilloma viruses types 16, 18, 33, 45 (adult ce ⁇ -vical cancer), and the bacterium Helicobacter pylori (B cell gastric lymphoma).
• EBV Epstein Ban- vims
• HTLVL adult T cell leukemia
• Hcogenic human papilloma viruses types 16, 18, 33, 45 adult ce ⁇ -vical cancer
• Helicobacter pylori B cell gastric lymphoma
• Other medically relevant microorganisms that may serve as antigens in mammals and more particularly humans are described extensively in the literature, e.g.,
• the antigen in the cationic lipid complex comprises an antigen derived from or associated with a pathogen, i.e., a microbial antigen.
• the pathogen vaccines of the present invention further comprise at least one epitope of at least one microbial antigen.
• Pathogens that may be targeted by the subject vaccines include, but are not limited to, viruses, bacteria, parasites and fungi.
• the pathogen vaccines of the present invention further comprise a plurality of epitopes from one or more microbial antigens.
• the microbial antigens finding use in the cationic lipid complexes and methods may be inherently immunogenic, or nonimmunogenic, or slightly immunogenic.
• Exemplary antigens include, but are not limited to, synthetic, recombinant, foreign, or homologous antigens, and antigenic materials may include but are not limited to proteins, peptides, polypeptides, lipoproteins, lipopeptides, lipids, glycolipids, carbohydrates, RNA, and DNA.
• Exemplary viral pathogens include, but are not limited to, viruses that infect mammals, and more particularly humans.
• Retroviridae e.g., human immunodeficiency viruses
• HIV-I also referred to as HTLV-UI, LAV or HTLV-III/LAV, or HIV-III
• other isolates such as HIV-LP
• Picornaviridae e.g. polio viruses, hepatitis A virus; enteroviruses, human Coxsackie viruses, rhinoviruses, echo viruses
• Calciviridae e.g. strains that cause gastroenteritis
• Togaviridae e.g. equine encephalitis viruses, rubella viruses
• Flaviridae e.g.
• coronoviridae e.g. coronaviruses
• Rhabdoviradae e.g. vesicular stomatitis viruses, rabies viruses
• Coronaviridae e.g. coronaviruses
• Rhabdoviridae e.g. vesicular stomatitis viruses, rabies viruses
• Filoviridae e.g. ebola viruses
• Paramyxovi ⁇ dae e.g. parainfluenza viruses, mumps vims, measles virus, respiratory syncytial virus
• Orthomyxoviridae e.g.
• influenza viruses Bungaviridae (e.g. Hantaan viruses, bunga viruses, phleboviruses and Nairo viruses); Arena viridae (hemorrhagic fever viruses); Reoviridae (e.g.
• reoviruses reoviruses, orbiviurses and rotaviruses
• Birnaviridae Hepadnaviridae (Hepatitis B virus); P arvo viridae (parvoviruses); Papovaviridae (papilloma viruses, polyoma viruses); Adenoviridae (most adenoviruses); Herpesviridae herpes simplex virus (HSV) 1 and 2, varicella zoster virus, cytomegalovirus (CMV), herpes virus; Poxyiridae (variola viruses, vaccinia viruses, pox viruses); and Iridoviridae (e.g. African swine fever virus); and unclassified viruses (e.g.
• gram negative and gram positive bacteria may be targeted by the subject compositions and methods in vertebrate animals.
• Such gram positive bacteria include, but are not limited to Pasteurella species, Staphylococci species, and Streptococcus species.
• Gram negative bacteria include, but are not limited to, Escherichia coli, Pseudomonas species, and Salmonella species.
• infectious bacteria include but are not limited to: Helicobacter py lor is, Boretta burgdorferi, Legionella pneumophitia, Mycobacteria sps (e.g. M. tuberculosis, M. avium, M, intracellulare, M. kansai ⁇ , M, gordonae).
• Staphylococcus aureus Neisseria gonorrhoeae, Neisseria meningitidis, Listeria monocytogenes, Streptococcus pyogenes (Group A Streptococcus), Streptococcus agalacfiae (Group B Streptococcus), Streptococcus (viridans group), Streptococcus faecalis , Streptococcus bovis, Streptococcus (anaerobic sps,), Streptococcus pneumoniae, pathogenic Campylobacter sp., Enterococcus sp., Haemophilus infuenzae, Bacillus antracis, corynebacterium diphtheriae, corynebacterium sp., Erysipelothrix rhushpathiae, Clostridium per/ringers, Clostridium tetani, Enterobacter
• Polypeptides of bacterial pathogens which may find use as sources of microbial antigens in die subject compositions include but are not limited to an iron-regulated outer membrane protein, (“ ⁇ ROMP”), an outer membrane protein (“OMP”), and an A-protein of Aeromonis salmonicida which causes furunculosis, p57 protein of Renibacterium salmoninarum which causes bacterial kidney disease ("BKD"), major surface associated antigen ("msa”), a surface expressed cytotoxin (“mpr”), a surface expressed hemolysin (“ish”), and a flagellar antigen of Yersiniosis ⁇ an extracellular protein (“ECP”), an iron- regulated outer membrane protein (“IROMP”), and a structural protein of Pasteurellosis; an OMP and a flagellar protein of Vibrosis anguillarum and V.
• ⁇ ROMP iron-regulated outer membrane protein
• OMP outer membrane protein
• A-protein of Aeromonis salmonicida which causes furuncul
• antigens can be isolated or prepared recombinantly or by any other means known in the art.
• pathogens further include, but are not limited to, fungi that infect mammals, and more particularly humans.
• fungi include, but are not limited to: Cryptococcus neoformans, Histoplasma capsulation, Coccidioides immitis, Blastomyces dermatitidis, Chlamydia trachomatis, and Candida albicans.
• infectious parasites include Plasmodium such as Plasmodium falciparum, Plasmodium mala ⁇ ae, Plasmodium ovale, and Plasmodium vivax.
• Other infectious organisms i.e. protists
• Polypeptides of a parasitic pathogen include but are not limited to the surface antigens of Ichthyophthirius.
• compositions and methods of the present invention are useful for treating infections of nonhuman mammals.
• Many vaccines for the treatment of nonhuman mammals are disclosed in Bennett, K. Compendium of Veterinary Products, 3rd ed. North American Compendiums, Inc., 1995; see also WO 02/069369, the disclosure of which is expressly incorporated by reference herein in its entirety.
• nonhuman pathogens include, but are not limited to, mouse mammary tumor virus (“MMTV”), Rous sarcoma virus (“RSV”), avian leukemia virus ( 1 ALV”), avian myeloblastosis virus (“AMV”), murine leukemia virus (“MLV”), feline leukemia virus (“FeLV”), murine sarcoma virus (“MSV”), gibbon ape leukemia virus (“GALV”), spleen necrosis virus (“SNV”), reticuloendotheliosis virus (“RV”), simian sarcoma virus (“SSV”), Mason-Pfizer monkey virus (“MPMV”), simian retrovirus type 1 (“SRV-I "), lentiviruses such as HIV-I, H ⁇ V-2, SIV, Visna virus, feline immunodeficiency virus (“FIV”), and equine infectious anemia vires (“EIAV”), T-cell leukemia
• MMTV
• treatment refers to a prophylactic treatment which increases the resistance of a subject to infection with a pathogen or decreases the likelihood that the subject will become infected with the pathogen; and/or treatment after the subject has become infected in order to fight the infection, e.g., reduce or eliminate the infection or prevent it from becoming worse.
• Microbial antigens can be prepared by methods well known in the art. For example, these antigens can be prepared directly from viral and bacterial cells either by preparing crude extracts, by partially purifying the antigens, or alternatively by recombinant technology or by de novo synthesis of known antigens.
• the antigen may also be in the form of a nucleic acid encoding an antigenic peptide in a form suitable for expression in a subject and presentation to the immune system of the immunized subject. Further, the antigen may be a complete antigen, or it may be a fragment of a complete antigen comprising at least one epitope.
• the antigen may be conjugated to a lipid chain in order to improve its solubility in the hydrophobic acyl chains of the cationic lipid, while maintaining the antigenic properties of the molecule.
• the lipidated antigen can be a lipoprotein, or a lipopeptide, and combinations thereof.
• the lipidated antigen may have a linker conjugated between the lipid and the antigen such as, for example, an N-terminal ⁇ or ⁇ -paltnitoyl lysine may be connected to antigen via a dipeptide Ser-Ser linker.
• Application No. 12/049,957 discloses that the DOTAP/E7-lipo ⁇ eptide complex exhibited an enhanced functional antigen-specific CD8 ⁇ T lymphocyte responses in vivo compared to the DOTAP/E7 formulation, and therefore provided superior anti-tumor efficacy.
• TC-I cells are C57BL/6 mouse lung endothelial cells that have been transformed with the HPVl 6 E6 and E7 oncogenes and activated H-ras. Cells were grown in RPMI medium
• the MHC class I restricted peptide from the HPV 16 E7 protein (amino acid 11 to 20, YMLDLQPETT [SEQ.
• DOTAP liposomes were prepared by thin film hydration followed by extrusion.
• the lipid, in chloroform, was dried as a thin layer under a stream of nitrogen in a glass tube.
• the thin film was vacuum desiccated for 2-3 Ii and then re-hydrated in cell culture grade water (commercially available from Ca ⁇ nbrex of Walkersville, MD) or buffer (such buffers are well known to those skilled in the art) containing E7 peptide to a final concentration of 0.7 mg lipids and 0.1 mg E7 per mL (molar ratio- 11 :1).
• the lipid dispersion was sequentially extruded through polycarbonate membranes with pore size of 0.4, 0.2, and 0.1 ⁇ m.
• E7 peptide association with the liposome was determined by measuring the percentage of liposome- bound peptide.
• unbound E7 peptide from R-DOTAP/E7, S-DOTAP/E7 or RS- DOTAP/E7 complexes was separated by a Microcon ® centrifugal filtrate device (Millipore, Bedford, MA) and the concentration of unbound peptide was measured by Micro BCATM Protein Assay Kit (Pierce, Rockford, IL). The efficiency of peptide association was determined as percent unbound peptide.
• Other methods used in general liposome preparation that are well known to those skilled in the art may also be used.
• LGM-3 medium commercially available from Lonza of Walkers ville, MD
• IL-4 and GM-CSF 50 microgram/ml IL-4 and GM-CSF at 37 0 C and 5% CO 2 at an initial plating density of 125,000 cells/cm 2 in 2 ml of medium in 12-well tissue culture dishes.
• the cells were grown for 3 days in culture and appeared as a mixture of adherent and rounded cells by microscopic examination.
• IL-4 and GM-CSF all wells
• test wells were treated with either a mixture of intedeukin 1-beta ("IL-P"), mterleukin 6 (" ⁇ L-6") and TNF- ⁇ at 10 ng/nil, and prostaglandin E2 ("PGE-2") at 10 ⁇ g/mJ (positive control for activation), no treatment (negative activation control), and S- DOTAP/E7 at 2.5, 10 and 40 micromolar final concentrations, and R-DOTAP/E7 at 2.5, 10 and 40 micromolar final concentrations.
• IL-P intedeukin 1-beta
• ⁇ L-6 mterleukin 6
• TNF- ⁇ 10 ng/nil
• PGE-2 prostaglandin E2
• the treated dendritic cells were maintained in culture for 24 hours and harvested for cell surface marker staining and flow cytometry analysis.
• the harvested cells were counted by hemacytometer and 10 ⁇ l of the following antibody conjugates were added sequentially to each sample for labeling surface markers: CD80-FITC, CD83-APC, and CD86-PE (BD Biosciences).
• the surface labeled cells were subsequently analyzed by flow cytometry using a BD FACxcaliber flow cytometer, and the co -stimulatory dendritic cell marker molecules CD80, CD83, and CD86 which are produced upon activation, were monitored.
• Cationic Upid/ E7 complexes consisting of individual R and S enantiomers exhibit different potencies in activating human dendritic cells to induce chemokine and cytokine production
• Human HLA-A2 dendritic cells (Lonza, Walkersville, MD), were treated and grown in culture as described above. On day 3 the cells were treated with 40 micromolar DOTAP/E7 complex or the potent immimostimulator lipopolysaccharide (LPS) at 50 micromolar concentrations (positive control). Medium from assay wells was removed and centrifuged at 1300 rpm in a microfuge for 5 minutes to pellet unattached dendritic cells.
• LPS potent immimostimulator lipopolysaccharide
• mice were subcutaneously injected with TC-I cells on day 0 in order to induce the growth of HPV-positive tumors.
• the DOTAP/E7 compositions were comprised of racemic mixtures of DOTAP.
• the mice received DOTAP/E7 compositions containing 10 ⁇ g E7 peptide subcutaneously on the opposite side of the abdomen on day 6 DOTAP lipid concentration in the complex varied from 3 to 600 nmole (3, 15, 30, 75, 150, 300, and 600 nmole).
• mice given a high dose of DOTAP did not show anti-tumor activity, confirming that DOTAP liposomes at a high dose might have induced a negative regulation to the immune response,
• DOTAP liposomes at the 100 nmole dose, but without E7 peptide did not show significant inhibition of tumor growth, indicating that the anti-tumor effect was antigen specific.
• DOPG 1,2- dioieoyl-sn-gIycero-3-phosphoglycerol
• mice were subcutaneously injected with TC-I cells on day 0 in order to induce the growth of HPV-positive tumors.
• the mice received R and S- DOTAP /E7 compositions containing 20 ⁇ g E7 peptide subcutaneous iy on the opposite side of the abdomen on day 6.
• R or S-DOTAP lipid concentrations in the complex varied from 3 to 600 nmole (3, 15, 30, 75, 100, 125, 150, 300, and 600 nmole).
• mice given a high dose of R-DOTAP did not show significant anti-rumor activity, confirming that R-DOTAP liposomes at a high dose might have induced a negative regulation to the immune response.
• E7 peptide alone did not show any inhibition of tumor growth (not shown).
• Figure 15 shows the lipid dose-response curves for the tumor regression efficacy of the various cationic lipid/E7 antigen complexes DOTAP, S-DOTAP 3 and R- DOTAP at 20 ⁇ g of the antigen and DOTAP at 10 ⁇ g of the antigen. [QOl ⁇ l] 8. Induction of T cell proliferation by S-DOTAP and R-DOTAP compositions.
• DOTAP/E7 interacts directly with human T lymphocytes, leading to clonal expansion and T cell activation.
• Those studies examined the ability of race ⁇ iic mixtures of DOTAP to stimulate clonal expansion of T cells.
• enriched hitman lymphocytes obtained from an HLA- A2 + healthy donor were directly stimulated by medium, DOTAP alone, peptide alone or DOTAP/hE7. The stimulation was repeated three times with a 7-day interval. Three days after the third stimulation, lymphocytes treated with DOTAP or D0TAP/E7 showed extensive expansion of T cell colonies in culture in contrast to no clonal expansion in medium control. The expanded T ⁇ cells also demonstrated significant CTL activity.
• DOTAP-mediated T cell activation was further confirmed by ERK phosphorylation in T cells, DOTAP-induced expression of die co stimulatory molecule, CD86 on human T lymphocytes was also observed. Those results suggested that DOTAP has a direct impact on T cell activation via a MAP kinase mediated cell proliferation. [00104[ In the present studies, the induction of human T-cell proliferation by the R and
• a broad class of cationic lipids can act as potent immvino stimulators together with an antigen to generate antigen specific immune responses in the treatment of disease.
• U.S. Patent No. 7,303,881 discloses that liposomes comprised of cationic lipids activate dendritic cells as demonstrated by the stimulation by cationic lipids of the expression of costimulatory molecules CD80/CD86 on DC2.4 dendritic cells ( Figure 14A and 14B).
• the ability to stimulate the expression of CDS0/CD86 on DC2.4 cells by different cationic liposomes varies greatly.
• Lipofectamine.RTM. a 3:1 (w/w) liposome formulation of the polycationic lipid 2,3-dioleyloxy-N-[2(sperminecarboxaraido)ethy3]-N,N- dim ethyl- 1 -propanamini- um trif ⁇ oro acetate (DOSPA) and the neutral lipid dio ⁇ eoyl phosphatidylethanolamine (DOPE), and liposomes prepared from O,O'-dimyristyl-N-lysyl aspartate (DMKE) and O,O'-dimyristyl-N-lysyl-glutamate (DMKD), strongly stimulated the expression of CD80/CD86 by CD2.4 cells.
• DOSPA polycationic lipid 2,3-dioleyloxy-N-[2(sperminecarboxaraido)ethy3]-N,N- dim ethyl- 1 -propanamini- um trif ⁇ oro
• cationic lipids are not only efficient targeting and delivery vehicles for antigens to APC of the immune system, but also function as potent adjuvants under low dose composition ranges to directly influence immune system function through activation of MAP kinase dependent signaling pathways with resultant production of immune system regulatory molecules including cytokines and chemokines.
• a clear dose-response effect of cationic lipid on the immuno stimulatory capabilities of the formulations have been demonstrated. It was demonstrated that upon receiving the l ⁇ pid/antigen complex, the particles were mainly taken up by dendritic cells, the major professional antigen presenting cells.
• the initiation of dendritic cell activation and migration to the draining lymph node facilitates immune responses against antigen specific TC-I tumors as demonstrated.
• Functional CD8 + T lymphocytes were generated in mice upon receiving a DOTAP/E7 injection and tumor sizes decreased and exhibited enhanced apoptosis, owing to the increasing number of infiltrating T cells in the tumor microenviiOnment.
• the resulting bell-shaped (activity decreases above and be ⁇ ow the optimal dose) cationic lipid dose response curve demonstrated activity at very low doses, indicating mat the activity of the cationic lipids as adjuvants or immunostimulators is so potent that the EC 50 is as low as about 15 nmole per injection.
• cationic lipids eliminate the immuno stimulatory activity.
• an antigen such as, for example, ovalbumin
• Cationic liposomes can also induce expression of the co -stimulatory molecules CD80 and CD83 and activate human dendritic cells.
• the cationic lipids and cationic lipid/ antigen complexes in addition to effective delivery to the dendritic cells are potent activators of the immune system and provide simple, safe, and very efficient immunotherapies useful in preventing and treating diseases.
• further studies were performed to evaluate the effect of chirality in cationic lipids and the imi ⁇ iuno stimulatory capability of cationic lipids. To this effect pure synthesized R and S enantiomers of DOTAP were utilized and compared with, the commonly utilized racemic mixture.
• An important characteristic of an immunostimulator capable of inducing cellular immune responses to disease is its ability to induce the production of critical chemokines and cytokines. As reported in the Example, significant differences were observed between the R and S enantiomers of DOTAP in their ability to induce chemokine and cytokine production. R-DOTAP was observed to be a more potent immune activator than S-DOTAP. In all cases the potency of R-DOTAP was equivalent to or higher than that of the DOATP racemic mixture.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Organic Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Immunology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Epidemiology (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Virology (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Medicinal Preparation (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Peptides Or Proteins (AREA)

Priority Applications (14)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=41199446

Family Applications (1)

Country Status (13)

Cited By (21)

Families Citing this family (8)

Citations (8)

Family Cites Families (115)

• 2009
  • 2009-04-14 BR BRPI0910464-0A patent/BRPI0910464B1/pt active IP Right Grant
  • 2009-04-14 PL PL09733034T patent/PL2276495T3/pl unknown
  • 2009-04-14 ES ES09733034T patent/ES2712505T3/es active Active
  • 2009-04-14 RU RU2010146655/15A patent/RU2530555C2/ru active
  • 2009-04-14 WO PCT/US2009/040500 patent/WO2009129227A1/en not_active Ceased
  • 2009-04-14 EP EP09733034.4A patent/EP2276495B1/en active Active
  • 2009-04-14 AU AU2009236306A patent/AU2009236306B2/en active Active
  • 2009-04-14 CN CN200980121761XA patent/CN102137675A/zh active Pending
  • 2009-04-14 JP JP2011505132A patent/JP5971945B2/ja active Active
  • 2009-04-14 US US12/988,236 patent/US9789129B2/en active Active
  • 2009-04-14 CN CN201811312211.3A patent/CN110075113A/zh active Pending
  • 2009-04-14 CA CA2721366A patent/CA2721366C/en active Active
  • 2009-04-17 TW TW098112878A patent/TWI449534B/zh active
• 2010
  • 2010-10-14 IL IL208713A patent/IL208713A/en active IP Right Grant
• 2017
  • 2017-09-12 US US15/702,063 patent/US10702541B2/en active Active
• 2020
  • 2020-06-12 US US16/899,763 patent/US11801257B2/en active Active
• 2021
  • 2021-03-25 US US17/212,051 patent/US20210308157A1/en not_active Abandoned

Patent Citations (9)

Non-Patent Citations (17)

Also Published As

Similar Documents

Legal Events